Deferasirox

Generic Name: Deferasirox

Brand Names: Exjade, Jadenu, 恩瑞格, Deferasirox Accord, Deferasirox Mylan

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₅N_₃O_₄

CAS Number: 201530-41-8

Unique Ingredient Identifier: V8G4MOF2V9

Background: Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.

Indication: For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.

Associated Conditions: Chronic Iron Overload

Associated Therapies: -

Clinical Trials

Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox

Completed

Conditions: Transfusional Hemosiderosis

Interventions: Drug: deferasirox

First Posted Date: 2011-07-14

Last Posted Date: 2016-02-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 120

Registration Number: NCT01394029

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Effects of Iron Loading and Iron Chelation Therapy on Innate Immunity During Human Endotoxemia

Not Applicable

Completed

Conditions: Anemia
Systemic Inflammatory Process

Interventions: Drug: iron sucrose
Drug: Deferasirox
Drug: endotoxin
Drug: Placebo

First Posted Date: 2011-05-06

Last Posted Date: 2015-11-17

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 30

Registration Number: NCT01349699

Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload

Phase 4

Completed

Conditions: Iron Overload

Interventions: Drug: deferasirox

First Posted Date: 2011-04-13

Last Posted Date: 2012-05-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT01335035

Locations: 🇪🇸
Novartis Investigative Site, Murcia, Spain

Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study

Phase 4

Terminated

Conditions: Myelodysplastic Syndrome
Transfusional Iron Overload

Interventions: Drug: Deferasirox

First Posted Date: 2011-03-31

Last Posted Date: 2017-03-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 12

Registration Number: NCT01326845

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain

Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda

Phase 2

Conditions: Porphyria Cutanea Tarda

Interventions: Drug: Exjade

First Posted Date: 2011-01-27

Last Posted Date: 2011-01-27

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 45

Registration Number: NCT01284946

Locations: 🇫🇷
Hopital Louis Mourier, GI unit,, Colombes, Ile de France, France

Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies

Phase 2

Completed

Conditions: Adult Langerhans Cell Histiocytosis
Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Grade III Lymphomatoid Granulomatosis
Angioimmunoblastic T-cell Lymphoma
Contiguous Stage II Adult Burkitt Lymphoma
Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma
Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma

Interventions: Drug: deferasirox
Other: laboratory biomarker analysis
Other: enzyme-linked immunosorbent assay

First Posted Date: 2011-01-10

Last Posted Date: 2018-09-07

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 16

Registration Number: NCT01273766

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.

Phase 4

Completed

Conditions: Myelodysplastic Syndrome
Thalassemia

Interventions: Drug: Deferasirox

First Posted Date: 2010-12-01

Last Posted Date: 2016-12-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 111

Registration Number: NCT01250951

Locations: 🇷🇺
Novartis Investigative Site, St. Petersburg, Russian Federation

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

Phase 2

Terminated

Conditions: Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Atypical Chronic Myeloid Leukemia, BCR-ABL Negative
de Novo Myelodysplastic Syndromes
Iron Overload
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Chronic Eosinophilic Leukemia